MGTX
MeiraGTxDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Bull case assumes positive clinical readouts and at least one partnering/licensing deal within three months that materially de-risks programs and accelerates milestones, prompting re-rating versus peers.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +2.6.
What can break
Clinical trial failure or safety signal
Momentum
93
Value
48
Sentiment
2
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.33 · Bull $9.38 · Bear $3.52
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $28.38
Why
Momentum93 · Δ7d +2.6
Value48 · Δ7d -0.1
Sentiment2 · Δ7d +1.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
93
26% active weight
Current posture
7d trendImproving
Δ7d
+2.6
Δ21d
+16.0
Value
48
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.0
Sentiment
2
34% active weight
Current posture
7d trendImproving
Δ7d
+1.5
Δ21d
-2.8
Why this grade
Composite grade D. Momentum 93.5 / Value 48.5 / Sentiment 1.5
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.15B
Beta
1.38
Shares Out
92.61M
P/E (TTM) · Derived
-8.8
P/S (TTM)
22.17
P/FCF (TTM) · Derived
265.81
Rev YoY
-84.8%
EPS YoY
+12.6%
Gross Margin
+79.8%
Op Margin
-597.9%
Net Debt
$22.76M
Current Ratio
0.55
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology